Tag - PRTK

The results of Paratek Pharmaceuticals’ (NASDAQ:PRTK) Phase 3 trial of NUZYRA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) have been published in the peer-reviewed journal, The Lancet...